Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).
This is written in the approval document as:
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)
Citation
Brentuximab vedotin and ICE Therapy, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 +, HER2-negative | Hodgkin Lymphoma | Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide |